Wednesday, June 4, 2025

Transcripta Bio & Microsoft team up on AI disease research

Related stories

Snowflake Buys Crunchy Data for Enterprise Postgres in AI Cloud

Empowering enterprises across industries to build and deploy secure,...

Immuta Unveils AI to Speed Enterprise Data Provisioning

First-to-market features enable real-time, intelligent access decisions—eliminating manual reviews...

Cube Unveils D3: Agentic Analytics on Semantic Layer

Cube, the leading provider of semantic layer technology for...

IBM Launches watsonx AI Labs to Boost AI in NYC

New AI initiative will co-create gen AI solutions with...

Oxipital AI & Schmalz Partners for Advanced Automation

Oxipital AI, a pioneering force in AI-driven machine vision...
spot_imgspot_img

Transcripta Bio announced a research collaboration with Microsoft Research to accelerate the discovery of disease-gene associations using advanced artificial intelligence (AI) and large-scale transcriptomic data. This collaboration brings together Transcripta Bio’s proprietary Drug-Gene Atlas, which contains over a billion gene responses and full-transcriptome data, and Microsoft Research’s machine learning expertise with the goal of identifying novel therapeutic opportunities faster and with more certainty than conventional methods.

Transcripta Bio and Microsoft Research will analyze chemotranscriptomic datasets with a primary goal to identify candidate disease-gene associations supported by experimental evidence of gene expression modulation. The teams hope to accelerate the path from discovery to clinical candidate selection, with the potential for fast-tracking and delivering new therapies to patients more efficiently.

Also Read: Voiant Unveils Hub 2.0 at ASCO, Sets Imaging Standard

Scott Saponas, Senior Director and Deputy Lab Director, Microsoft Research Health Futures, stated: “We are excited to collaborate with Transcripta Bio to leverage our expertise in rare disease genomics and AI, aiming to develop innovative methods for drug discovery that can significantly impact the treatment of rare diseases.”

Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, commented: “This collaboration with Microsoft Research enables us to scale our transcriptomics-driven approach, leveraging Microsoft’s computational resources and AI expertise. Together, we are setting a new standard for the speed, certainty, and efficiency of drug discovery.”

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img